New liposome chemo shows promise for High-Risk leukemia patients
NCT ID NCT02286726
First seen Mar 16, 2026 · Last updated May 19, 2026 · Updated 5 times
Summary
This study tested a new chemotherapy drug called CPX-351 in 56 adults with a fast-growing blood cancer (acute myeloid leukemia) that is hard to treat. The drug combines two standard chemo medicines inside a tiny fat bubble to help them work better together. The goal was to see how well it could put the cancer into remission and what side effects might occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.